Sol_75N98027Q00064.pdf

REQUEST FOR QUOTATION

(THIS IS NOT AN ORDER)

THIS RFQ IS IS NOT A SMALL BUSINESS SET-ASIDE

15. DATE OF QUOTATION

16. SIGNER

a. NAME (Type or print)

c. TITLE (Type or print)

b. TELEPHONE

AREA CODE

NUMBER

STANDARD FORM 18 (REV. 6/1995)

Prescribed by GSA-FAR (48 CFR) 53.215-1(a)

AUTHORIZED FOR LOCAL REPRODUCTION

Previous edition not usable

8. TO:

b. COMPANYa. NAME

c. STREET ADDRESS

d. CITY e. STATE f. ZIP CODE

9. DESTINATION

a. NAME OF CONSIGNEE

b. STREET ADDRESS

d. STATE e. ZIP CODE

7. DELIVERY

FOB DESTINATION

OTHER

(See Schedule)

10. PLEASE FURNISH QUOTATIONS TO THE

ISSUING OFFICE IN BLOCK 5a ON OR BEFORE CLOSE OF BUSINESS (Date)

IMPORTANT: This is a request for information and quotations furnished are not offers. If you are unable to quote, please so indicate on this form and return it to the address in Block 5a. This request does not commit the Government to pay any costs incurred in the preparation of the submission of this quotation or to contract for supplies or service. Supplies are of domestic origin unless otherwise indicated by quoter. Any representations and/or certifications attached to this Request for Quotation must be completed by the quoter.

11. SCHEDULE (Include applicable Federal, State and local taxes)

ITEM NUMBER

(a)

SUPPLIES/SERVICES

(b)

QUANTITY

(c)

UNIT

(d)

UNIT PRICE

(e)

AMOUNT

(f)

12. DISCOUNT FOR PROMPT PAYMENT

a. 10 CALENDAR DAYS (%) b. 20 CALENDAR DAYS (%) c. 30 CALENDAR DAYS (%) d. CALENDAR DAYS

NUMBER PERCENTAGE

NOTE: Additional provisions and representations are are not attached.

13. NAME AND ADDRESS OF QUOTER

a. NAME OF QUOTER

b. STREET ADDRESS

c. COUNTY

d. CITY e. STATE f. ZIP CODE

14. SIGNATURE OF PERSON AUTHORIZED TO

SIGN QUOTATION

PAGE OF PAGES

1. REQUEST NUMBER 2. DATE ISSUED 3. REQUISITION/PURCHASE REQUEST NUMBER 4. CERT. FOR NAT. DEF.

UNDER BDSA REG. 2

AND/OR DMS REG. 1

RATING

5a. ISSUED BY 6. DELIVER BY (Date)

NAME TELEPHONE NUMBER

AREA CODE NUMBER

c. CITY

5b. FOR INFORMATION CALL (NO COLLECT CALLS)

National Institutes of Health OD - Office of Logistics and Acquisition Operations 6100 Executive Blvd., Room 6B05 Bethesda, MD 20892-7511

75N98027Q00064

JOHN JOHNSON

+10

000-000000

11/04/2026

12/14/2026 1400 ES

Multiple

The purpose of this COMBINED

SYNOPSIS/SOLICITATION (Brand name or only) is to acquire a PERIMED PeriFlux

6000 combined system.

The following FAR clauses and Provisions are applicable to this award.

FAR 52.204-13 System for Award

Management Maintenance (Oct 2018)

FAR 52.204-18 Commercial and Government

Entity Code Maintenance (Aug 2020)

HHSAR 352.222-70, Contractor Cooperation in Equal Employment Opportunity

Investigations (Dec 2015)

FAR 52.212-4 Contract Terms and

Continued...

1 7

CONTINUATION SHEET

REFERENCE NO. OF DOCUMENT BEING CONTINUED PAGES

NAME OF OFFEROR OR CONTRACTOR

SUPPLIES/SERVICES

(B)

UNIT

(D)

UNIT PRICE

(E)

AMOUNT

(F)

OPTIONAL FORM 336 (4-86)

Sponsored by GSA FAR (48 CFR) 53.110

ITEM NO.

(A)

QUANTITY

(C)

NSN 7540-01-152-8067

75N98027Q00064

Conditions -In addition to all the applicable commercial Products and Commercial Services

(Nov 2023)

FAR 52.212-5 Contract Terms and Conditions

Required to Implement Statutes or Executive

Orders/Commercial Products and Commercial

Services (Jan 2025)

FAR 52.217-8 Option to Extend Services (Nov

1999)

FAR 52.252-2 CLAUSES INCORPORATED BY REFERENCE

COMBINED SYNOPSIS / SOLICITATION (Brand Name or Equal)

Title: PERIMED PeriFlux 6000 combined system

(i) This is a combined synopsis/solicitation for commercial items prepared in accordance with FAR Subpart 12.6, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested, and a separate written solicitation will not be issued.

(ii) The solicitation number is 75N98027Q00064 PCA-NIA-11888. This solicitation is issued as a competitive combined synopsis/solicitation for commercial products or commercial services.

The Government intends to award a contract or purchase order resulting from this solicitation using full and open competition.

This acquisition is conducted under the authority of FAR 12.603, Streamlined Solicitation for Commercial Products or Commercial Services, and is not expected to exceed the simplified acquisition threshold.

The National Institutes of Health (NIH), Office of the Director, Office of Acquisitions, seeks to award a firm fixed-price award to the responsible offeror whose proposal represents the best value to the Government.

(iii) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular March 2026.

(iv) The associated NAICS code is 334516, and the small business size standard is “Other Than Small Business”

• This requirement is NOT set aside for Small Business

(v) Description of Requirement:

Purchase Description:

Item Number Description Quantity

93-00202-2 Heat, 2TC PeriFlux 6000 Combined System 1 41990120 D826 Membraning Kit tcpO2 (12 pcs) 6

90-00054 TC 555 Fixation Ring for tcpO2 – Extra Strength Adhesive (50 pcs) and TC 560 Contact Liquid 8

93-00006 PF 105-3 Double-sided Tape Strip (100 pcs) 4 training1 Training and Installation (On-site) 1 sa1 Support Agreement – PF 6000 Combined System 2 90-00066 PeriFlux 6000 EPOS 1 93-00233 PF 105-1 Double-sided Tape Ring (102 pcs) 3

(vi) Delivery Location:

NIH/NIA

251 Bayview Blvd STE 100

Baltimore MD 21224

(vii) [Reserved, if needed]

(viii) FAR 52.204-7, System for Award Management, applies to this acquisition.

(ix) The provision at FAR 52.212-1, Instructions to Offerors—Commercial Items, applies to this acquisition. Add any agency-specific instructions as required.

(x) The provision at FAR 52.212-2, Evaluation—Commercial Items, applies to this acquisition.

(a) The Government will award a contract resulting from this solicitation to the responsible offeror whose offer conforming to the solicitation represents the best value to the Government, price and other factors considered.

(b) Evaluation Factors:

• Price

• Technical capability

• Past performance

• Delivery schedule

(c) A written notice of award or acceptance of an offer, issued within the time specified in the offer, shall result in a binding contract without further action by either party. The Government reserves the right to accept any offer before the expiration date.

(xi) FAR 52.212-4, Contract Terms and Conditions—Commercial Items, applies to this acquisition.

(xii) Additional contract requirements or terms and conditions, as determined necessary by the Contracting Officer and consistent with customary commercial practices:

(None)

(xiii) The Defense Priorities and Allocations System (DPAS) is (not applicable).

(xiv) Submission Requirements:

Responses must include sufficient information to demonstrate the offeror’s capability to provide the required product or service. Quotes shall include, at a minimum:

• Unit and total price

• Shipping and handling costs

• Delivery timeframe after award

• Delivery terms

• F.O.B. point (destination or origin)

• Product or catalog numbers (if applicable)

• Product/service description

Additional evaluation considerations may include past performance, warranty, lifecycle cost, maintenance availability, and environmental or energy efficiency.

Responses must include the Unique Entity Identifier (UEI), Taxpayer Identification Number (TIN), and business size certification. All offerors must be actively registered in the System for Award Management (SAM) at www.sam.gov.

All responses must be received by (December 14, 2026, 2PM, EST) and must reference solicitation number 75N98027Q00048/PCA-NIA-12240 Responses may be submitted electronically to johnsonjr@mail.nih.gov.

(xv) Point of Contact:

John Johnson, Program Specialist, johnsonjr@mail.nih.gov 667-312-5580.

mailto:johnsonjr@mail.nih.gov mailto:johnsonjr@mail.nih.gov

Version 11-30-2016-1 FAR Part 11—Describing Agency Needs

PURCHASE DESCRIPTION

1. Statement of Need and Purpose:

The Clinical Research Unit requires an integrated, validated system capable of quantifying both macrocirculatory function (ankle-brachial index, toe-brachial index, segmental limb pressures, and pulse volume recordings) and microcirculatory function (transcutaneous oxygen tension, laser Doppler skin perfusion, and skin perfusion pressure) within a single standardized clinical research visit. No equipment currently available to the Clinical Research Unit meets this combined macro/microvascular assessment need in one platform; assessments are presently fragmented across disparate devices, which limits throughput, standardization, and the ability to correlate macro- and micro-level vascular findings within the same participant encounter.

The purpose of this acquisition is to equip the NIA Clinical Research Unit with a combined macro-and microvascular diagnostic platform to enable standardized, protocol-driven vascular assessment in BLSA and GESTALT participants, support direct within-subject comparison of macro- and microvascular status, and generate longitudinal vascular biomarker data linkable to the broader BLSA/GESTALT datasets. Without this system, the Clinical Research Unit will continue to rely on fragmented, non-integrated equipment, constraining the scientific scope of BLSA and GESTALT in characterizing vascular contributions to aging phenotypes and delaying the generation of combined macro/microvascular biomarker datasets that are increasingly central to aging and geriatric vascular research.

2. Background Information and Objective:

The Clinical Research Unit of the National Institute on Aging (NIA) conducts two major longitudinal studies of human aging — the Baltimore Longitudinal Study of Aging (BLSA) and GESTALT (Genetic and Epigenetic Signatures of Translational Aging Laboratory Testing). Both studies require comprehensive, repeatable, non-invasive physiological phenotyping of participants across the adult lifespan in order to characterize the trajectories of biological aging and identify early biomarkers of age-related disease.

Vascular health is a central determinant of healthy aging. Both macrovascular disease (peripheral arterial disease, critical limb ischemia) and microvascular dysfunction (impaired skin and tissue perfusion, reduced microcirculatory reserve) are known to progress silently with age and are independently associated with frailty, impaired wound healing, cardiovascular morbidity, and mortality. Capturing both levels of circulatory function — macrocirculatory (large vessel) and microcirculatory (capillary-level perfusion and oxygenation) — in the same cohort of participants over time is essential to understanding how vascular aging contributes to the broader aging phenotype studied by BLSA and GESTALT.

Peripheral vascular dysfunction is both a consequence and an accelerant of aging-related decline. Macrovascular disease (e.g., PAD) restricts blood flow to the limbs and is linked to impaired mobility and increased cardiovascular risk, while microvascular dysfunction impairs tissue oxygen delivery and wound healing, and is increasingly recognized as an early, sensitive marker of systemic vascular aging — often preceding overt macrovascular disease.

By incorporating combined macro/microvascular phenotyping into BLSA and GESTALT, the CRU will be positioned to:

• Characterize the natural history and rate of progression of both macro- and microvascular aging in a well-characterized, longitudinally followed cohort.

Version 11-30-2016-1 FAR Part 11—Describing Agency Needs

• Investigate whether microvascular measures (tcpO2, laser Doppler perfusion, SPP) serve as earlier or more sensitive indicators of vascular aging than traditional macrovascular measures (ABI/TBI) alone.

• Examine associations between vascular function and other BLSA/GESTALT domains, including physical performance, body composition, inflammatory markers, and epigenetic aging clocks.

• Support investigations relevant to wound healing capacity, frailty, and functional decline

— outcomes of direct relevance to NIA's mission.

3. Generic Name of Product:

Non-invasive peripheral vascular diagnostic system (micro and macro circulation)

4. Purchase Description:

PERIMED PeriFlux 6000 combined system

5. Salient characteristics

PeriFlux 6000 Combined System (2-channel tcpO2, 2-channel Laser Doppler with heat), including bilateral PVR measurement capability on right and left forearms, plus the EPOS (Enhanced Perfusion and Tissue Oxygenation) module with additional consumables for 60 single evaluations.

Test capabilities:

• Toe/Ankle pressure

• TBI/ABI (Toe-Brachial Index / Ankle-Brachial Index)

• PVR (Pulse Volume Recording)

• tcpO2 (transcutaneous oxygen tension)

• SPP (Skin Perfusion Pressure)

• SLP (Segmental Limb Pressure, 3-cuff or 4-cuff method)

• Treadmill / stress testing

• Digit pressures

• EPOS (Enhanced Perfusion and Tissue Oxygenation)

System components:

• PF 6001 Main Unit

• PF 6010 LDPM/Temp Unit(s)

• PF 6040 tcpO2 Unit(s)

• PF 6050 Pressure Unit and PF 6051 Pressure Accessory Kit

• Laser Doppler Probe(s) and E5250 tcpO2 Electrode(s)

• Medical-grade Panel PC with PSW Examination Manager Software

• Ergonomic cart and camera

• Associated consumables (membrane kits, fixation rings, adhesive strips)

6. Quantity: 1 system

7. Delivery Date: FOB Destination; 4–6 weeks for the system, 1–2 weeks for accessories/consumables

8. Period of Performance: N/A – quote # 202609-13246 expiration date 12/01/2026

9. Option(s): N/A

Title